Rhenman & Partners Asset Management AB Increases Stock Holdings in Kura Oncology, Inc. $KURA

Rhenman & Partners Asset Management AB increased its holdings in Kura Oncology, Inc. (NASDAQ:KURA) by 78.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 872,000 shares of the company’s stock after purchasing an additional 382,000 shares during the period. Rhenman & Partners Asset Management AB owned 1.00% of Kura Oncology worth $9,060,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in KURA. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Kura Oncology by 6.3% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 50,008 shares of the company’s stock valued at $333,000 after purchasing an additional 2,977 shares during the period. Strs Ohio purchased a new stake in shares of Kura Oncology in the first quarter valued at $143,000. Legal & General Group Plc grew its position in shares of Kura Oncology by 35.1% in the second quarter. Legal & General Group Plc now owns 72,910 shares of the company’s stock valued at $421,000 after purchasing an additional 18,930 shares during the period. Rhumbline Advisers grew its position in shares of Kura Oncology by 13.0% in the second quarter. Rhumbline Advisers now owns 118,896 shares of the company’s stock valued at $686,000 after purchasing an additional 13,690 shares during the period. Finally, American Century Companies Inc. grew its position in shares of Kura Oncology by 244.5% in the second quarter. American Century Companies Inc. now owns 232,752 shares of the company’s stock valued at $1,343,000 after purchasing an additional 165,189 shares during the period.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on KURA shares. Wedbush lowered their price objective on Kura Oncology from $38.00 to $36.00 and set an “outperform” rating for the company in a research report on Friday, March 6th. Wall Street Zen raised Kura Oncology from a “strong sell” rating to a “hold” rating in a research report on Saturday, May 16th. Citigroup reissued a “market outperform” rating on shares of Kura Oncology in a research report on Thursday, May 28th. Mizuho lowered their price target on Kura Oncology from $30.00 to $25.00 and set an “outperform” rating for the company in a research report on Tuesday, March 24th. Finally, Oppenheimer set a $24.00 price target on Kura Oncology in a research report on Thursday, May 28th. Ten analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $25.58.

Kura Oncology Price Performance

KURA stock opened at $9.05 on Friday. The stock has a 50-day moving average price of $9.31 and a two-hundred day moving average price of $9.33. Kura Oncology, Inc. has a 12-month low of $5.45 and a 12-month high of $12.49. The company has a current ratio of 6.15, a quick ratio of 6.14 and a debt-to-equity ratio of 0.09. The company has a market cap of $803.37 million, a PE ratio of -2.70 and a beta of 0.36.

Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.83) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.05. Kura Oncology had a negative return on equity of 141.95% and a negative net margin of 411.19%.The firm had revenue of $18.27 million during the quarter, compared to the consensus estimate of $25.97 million. As a group, research analysts predict that Kura Oncology, Inc. will post -3.47 EPS for the current year.

Kura Oncology Company Profile

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.